Navigation Links
BioMS Medical Announces Second Quarter 2008 Results
Date:8/12/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Aug. 12 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the second quarter ended June 30, 2008. BioMS Medical, in partnership with Eli Lilly and Company (Lilly), is developing MBP8298 (dirucotide), a drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the US.

"The three randomized late-stage clinical trials for MBP8298 (dirucotide) continue to progress very well. We recently announced that MAESTRO-03, our U.S. phase III secondary progressive MS trial, was fully recruited with approximately 510 patients," said Kevin Giese, President and CEO of BioMS Medical. "During the quarter, BioMS was also honored to receive the Gold Leaf Award from BIOTECanada in recognition of our selection as "Company of the Year".

Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for MBP8298 (dirucotide):

(x) MAESTRO-01: A randomized, double-blind pivotal phase II/III trial in Canada and Europe evaluating MBP8298 (dirucotide) for the treatment of secondary progressive MS (SPMS). The study has completed full recruitment of 611 patients at 47 trial sites in 10 countries. Patients are administered either MBP8298 (dirucotide) or placebo every six months for a period of two years. To date, there have been eight positive safety reviews from the Data Safety Monitoring Board (DSMB).

(x) MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal trial. Eligible patients who have successfully completed the blinded, placebo controlled MAESTRO-01 trial may choose to receive MBP8298 (dirucotide) on an un-blinded basis. To date, approximately 95% of patients enrolled in MAESTRO-01 have proceeded to MAESTRO-02.

(x) MAESTRO-03: A U.S. pivotal phase III trial evaluating MBP8298 (dirucotide) for the treatme
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched ... tinnitus. Patients listen to sound therapy that is tailor-made ... weeks to months, their tinnitus volume decreases. , AudioNotch has ... and Notched White Noise. Now, AudioNotch is pleased to announce ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... on Advanced WiMAX Broadband Wireless Technology, Will, Provide Free Internet ... ... Sapir Community College, PETACH TIKVA, Israel, January 8 ... in Israel, today announced that it has joined,with Israel,s Ministry ...
... 7 Quest Diagnostics,Incorporated (NYSE: DGX ), ... services, announced that it is scheduled to speak,at ... January 8,2008, at the Westin St. Francis in ... to begin at 11:00 a.m. Eastern Time., ...
... NxStage Medical, Inc.,(Nasdaq: NXTM ), a leading ... has signed a five-year agreement with DaVita, Inc.,(NYSE: ... dialysis centers with,MasterGuard and ButtonHole safety needle sets, ... essential products used to access patients,blood during the ...
Cached Biology Technology:Israel's Ministry of Communications, 012 Smile.Communications, Intel and Alvarion Join in Launching WiMAX Initiative for Sderot, a City in the Western Negev 2Israel's Ministry of Communications, 012 Smile.Communications, Intel and Alvarion Join in Launching WiMAX Initiative for Sderot, a City in the Western Negev 3Israel's Ministry of Communications, 012 Smile.Communications, Intel and Alvarion Join in Launching WiMAX Initiative for Sderot, a City in the Western Negev 4Israel's Ministry of Communications, 012 Smile.Communications, Intel and Alvarion Join in Launching WiMAX Initiative for Sderot, a City in the Western Negev 5Quest Diagnostics to Speak at the 26th Annual JPMorgan Healthcare Conference 2NxStage Medical Announces Needle Supply Agreement with DaVita 2
(Date:4/18/2014)... For the past 20 years, researchers have published soil ... findings have suggested that soil organic carbon can be ... systems to no-till systems. However, there is a growing ... corn and soybean rotations without cover crops, small grains, ... stocks at the published rates. , "Some studies have ...
(Date:4/18/2014)... Asteroid and comet impacts can cause widespread ecological havoc, ... global scales. But new research from Brown University shows ... life at the time of an impact. , A ... found fragments of leaves and preserved organic compounds lodged ... Argentina. The material could provide a snapshot of environmental ...
(Date:4/17/2014)... A drug under clinical trials to treat tuberculosis ... drugs that act against various bacteria, fungal infections and ... University of Illinois chemists and collaborators. , Led by ... determined the different ways the drug SQ109 attacks the ... target other pathogens from yeast to malaria and ...
Breaking Biology News(10 mins):Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Multitarget TB drug could treat other diseases, evade resistance 2
... women who are obese may be more than twice as ... female teens who are not obese, according to a study ... Neurology , the medical journal of the American Academy of ... Health Study and Nurses, Health Study II who were 25 ...
... the hopeful news is that pediatric survival rates have ... enable survival often cause infertility. Boys ... an opportunity to preserve their fertility: before undergoing cancer ... in sperm banks. Younger boys, however, do not produce ...
... has completed a first draft of the cassava (Manihot esculenta) ... the pace of research on this subsistence crop and addressing ... the world. Cassava is a root crop that serves ... people each day. Although it has many properties that make ...
Cached Biology News:Teenage obesity linked to increased risk of MS 2For young boys with cancer, testicular tissue banking may be option to preserve fertility 2For young boys with cancer, testicular tissue banking may be option to preserve fertility 3Researchers complete draft genome sequence for cassava 2Researchers complete draft genome sequence for cassava 3Researchers complete draft genome sequence for cassava 4